text:
"Art On & Off the Walls" Guide Tracks the Hidden Masterpieces of Prescott
By Michael Grady | Yavapai College
From the stately lawns of Courthouse Plaza to the winding sidewalks of YC's Marcusen Sculpture Garden to the menagerie of lions, horses, heroes, dragons and eagles residing in galleries, office parks and alley murals all over town, Prescott has inspired a bounty of art. Each piece has its own story: the inspiration, the creation, the message it's trying to convey. Now, the Yavapai College Foundation and the American Association of University Women have collected these stories of Prescott's past to raise funds for its future.
The Prescott Branch of the American Association of University Women proudly unveils Art On & Off the Walls, a comprehensive guide to more than 30 well-known and little-known public art treasures in our community. Available for sale beginning September 17, Art On & Off the Walls will raise funds to support collegiate STEM scholarships for promising female students.
"Our Victorian Stroll last year was popular with the community and supplied generous funds for our scholarships," former AAUW Prescott Branch President Deb Dillon explained. "Since we know many are leery of indoor or group activities right now, we chose a fundraising opportunity that allows people to enjoy some of the wonderful outdoor art in our community on their own schedule."
Prescott's impressive public art portfolio ranges from iconic postcard images to heartfelt tributes to challenging abstracts. While many reside in galleries and public spaces, a surprising number of them linger in unlikely places. Art On & Off the Walls chronicles a variety of styles – Cowboy art, civic memorials, modern murals and Native-American creations – and turns the town you think you know into a kind of aesthetic scavenger hunt, telling the stories behind the works that people have seen – and pointing out a few pieces they may have overlooked.
"We used two teams," AAUW Scholarship Committee Co-chair Sandra Bennett explained, "'seekers,' who went around and looked for the art and gathered information about it, and writers who compiled the guide. "The information came from brochures, maps, and interviews at the sites."
The Art On & Off the Walls guide can be purchased with a $25 donation, beginning Friday, September 17. All proceeds will go to the AAUW's Centennial Scholarship at Yavapai College, which supports talented women students pursuing careers in Science, Technology, Engineering, or Math.
To make a donation and download the guide, please visit: www.yc.edu/aauwart. Those wishing to donate offline can mail their check to: Prescott AAUW, P.O. Box 10881, Prescott AZ. Please make checks payable to "Yavapai College Foundation," and include your email address, and you will receive the link to the guide.
Yavapai College operates six campuses and centers throughout Yavapai County and offers over 100 degrees and certificates, student and community services, and cultural events and activities. To learn more about YC, visit www.yc.edu.
American Association of University Women, Arizona, art, artworks, comprehensive guide, fundraising, Prescott, stories, Yavapai College, Yavapai College Foundation
Michael Grady | Yavapai College
PrevPreviousCongressman Paul Gosar Endorses David Livingston for State Treasurer
NextArizona Today: Interview with Sheriff Mark Dannels, Cochise CountyNext


text:
Search leaderpost.com
Regina Leader Post
Share this Story: Roughriders 39, Argonauts 28
Sask Election
Regina Votes
Cheer Fund 2020
Tech-Biz
Saskatchewan's Top Employers
Regina Pats
Roughriders 39, Argonauts 28
Rob Vanstone • Regina Leader-Post
Where does one start? Wow …
Maybe I should start with the start. The Riders are 3-0 for the second consecutive season. Over the first three games, the Riders have scored a league-high 114 points. That is the Riders' highest three-game regulation time total since 1988, when the Riders had 120 points over that span. The Riders had 115 points over the first three games in 2010, but 14 of those points were scored in overtime.
Roughriders 39, Argonauts 28 Back to video
Kory Sheets keeps increasing his CFL career-high rushing-yardage total … from 131, to 133, to 178. The latter total, gained during Thursday's 39-28 victory over Toronto, is the highest for a Roughrider since 2000. On Oct. 28, 2000, Darren Davis had 20 carries for 220 yards as the Riders beat Edmonton 54-52 in overtime. Davis had 199 yards after regulation time in that game.
Sheets has had 100-plus yards in the second half of each of the past two games. He had 16 carries for 129 yards over the final 30 minutes on Thursday.
Darian Durant left the game early in the fourth quarter with an injured right foot. Until being hurt, Durant had thrown three touchdown passes — fattening his season total to eight, without an interception. His efficiency rating is now a stratospheric 135.1.
Durant hit Taj Smith for touchdown bombs of 70 and 61 yards. Both of those TDs were one-play drives. For the record, the Roughriders had not thrown two TD passes of 61-plus yards in the same game since Sept. 1, 1996, when Kevin Mason (remember him?) found Curtis Mayfield for 87- and 85-yard majors in a 41-23 victory over Winnipeg. (Smith scored as many TDs on Thursday as he had all of last season. He now has three TDs after as many games this year.)
Rey Williams was outstanding (this is a recording). He had eight defensive tackles, two sacks and a pass knockdown. Moreover, he helped the Riders record FIVE sacks (with Graig Newman, Weldon Brown and Ricky Foley getting the others).
Tyron Brackenridge is a weapon at safety. His ferocious hitting is reminiscent of Ken MeEachern. Brackenridge also leads with his shoulder, as opposed to his head, which demonstrates a presence of mind in split-second situations.
Quirky stat: The Argos actually had more first downs (27 to 23). Very quietly, the Argos amassed 441 passing yards.
Import punter Ricky Schmitt continues to be a difference-maker. He averaged 43 yards per punt and (get this) 69 yards per kickoff.
The Roughriders' kick coverage continues to be outstanding. Chad Owens had 19 yards on four punt returns. He was also limited to 102 yards on five kickoff returns.
Saskatchewan's balance on offence is worth noting. The Roughriders won handily even though Weston Dressler (three catches for 22 yards) and Chris Getzlaf (one catch for 14 yards) had quiet nights.
And now, it's time to write another superlative-laden column about the Roughriders. Thank you and good-night.
Regina Leader Post Headline News
Sign up to receive daily headline news from Regina Leader-Post, a division of Postmedia Network Inc.
The next issue of Regina Leader Post Headline News will soon be in your inbox.
Follow the Regina Leader Post
© 2021 Regina Leader Post, a division of Postmedia Network Inc. All rights reserved. Unauthorized distribution, transmission or republication strictly prohibited.

redpajama_set_name: RedPajamaCommonCrawl


text:
Why The Senate Republicans Stifled Their 'Female Assistant'
Matthew Chapman
September 29 | 2018
Reprinted with permission from AlterNet.
For the Senate Judiciary Committee hearing on the sexual assault allegations brought by California psychology professor Christine Blasey Ford against Supreme Court nominee Brett Kavanaugh, Republicans brought in Rachel Mitchell, an Arizona sex crimes prosecutor, to question Ford and the judge on their behalf. But quickly into the Kavanaugh's testimony, senators pulled her away and began questioning Kavanaugh directly, with an unabashedly partisan, sympathetic bent.
In discussion with Chris Hayes on MSNBC, former assistant U.S. attorney Mimi Rocah weighed in on the shamelessness of Republicans ditching their own strategy to go after Ford when it started blowing up in their faces.
"That was no accident," said Rocah. "Here's the thing, look, I was not in favor of Ms. Mitchell being the one to ask questions, but she was there. I, as a former prosecutor, was embarrassed that she was there, as a professional law enforcement, sex crimes prosecutor who has worked with victims, would partake in this sham. But she was there. And you know what? Dr. Ford got her story out. And, even with Ms. Mitchell trying to cross-examine her, trying to poke holes in her, trying to show inconsistencies, nothing. Zero. They poked no holes that mattered. I mean, I think the biggest one, you know, midway through, was something about whether she had wanted to fly there or not. I mean, totally inconsequential. Her story came out clear. She remembered the big picture, the important details, didn't know some minor things but that's, you know, she explained, and we all know, it's common sense that's how human memory works."
"But," she continued, "when it came time for Kavanaugh to testify, and Mitchell started doing the same thing, she actually was asking him fact-based questions, and he was evasive, he couldn't answer them, and they did not want that to happen, and that is why she got fired on the spot. Because, to the extent this was at all a fact-finding exercise, which I think, you know, we've said many times on this show and others that it was pretty much a joke to call it that, but Ms. Mitchell actually added to that a little bit. Though they were having none of that, because he was not doing well with that. Once you got into facts with him, as soon as that started, he couldn't answer the questions, and so it had to get more political."
Chris Hayes agreed, and added another thought.
"I will say this," Hayes said. "She touched the stove, which was the calendar, July 1st. She said, 'You've got this thing on July 1st, Go to Timmy's for 'skis with Judge, the person who was in the allegation, and PJ, who is also in the allegation.' That's a Thursday, in July, of the summer, at a house with Judge and PJ and Brett Kavanaugh, all together, drinking. She got there, and that is when the blowup happened and she was fired."
Indeed, one of the final things Mitchell did touch upon before being removed was that date on Kavanaugh's calendar, which does appear to line up with Ford's story.
Between refusing to let the FBI investigate and refusing to call Judge as a witness, Republicans clearly wanted this hearing to be devoid of facts and to remain tethered to a he-said/she-said framework. Despite this, their own hired attorney came very close to uncovering real evidence against Kavanaugh — and soon after, she was gone from the room.
Matthew Chapman is a video game designer, science fiction author, and political reporter from Austin, TX. Follow him on Twitter @fawfulfan.


At Andover School of Montessori (ASM), we understand the importance of finding the right fit for your child's academic and social development. We also understand how vital the relationship between your family and our school is to your child's success at ASM. Visit ASM to explore our unique approach to developing your child's greatest potential. Apply to ASM to become a part of our remarkable community.


text:
Tuesday, 21 January 2020 News Before 1 Feb 2012. Click for Latest
Support for Government Compensation and Classification Act sought
San Fernando, Pampanga (26 October) -- The Civil Service Commission (CSC) initiated a signature campaign nationwide to support the immediate passage of the Government Compensation and Classification Act (GCA), a draft bill to rationalize and update the current compensation and position classification system in government.
The CSC, according to Regional Director Karin Litz Serna, believes that all government workers stand to gain from the approval of the GCA as it shall apply to constitutional bodies, departments, bureaus and agencies of the national government, state universities and colleges, government owned and controlled corporations (GOCCs) and government financial institutions (GFIs) with original charters.
In recognition of the autonomy of the Local Government Units (LGUs) as provided for in the Local Government Code, the GCA, according to Serna, shall not dictate on the compensation of their employees. The LGUs, however, may pattern their compensation structure on the GCA structure within their fiscal capability.
Serna added that the uniformed personnel of the Armed Forces of the Philippines (AFP) and the Philippine National Police (PNP) and all other agencies which adopted RA 6638 and RA 6648, as amended, are not covered in the GCA.
She enjoins government employees to affix their signatures on the sign-up forms available in CSC regional and field offices and other government offices. Further, groups and associations can make their support for the GCA felt by attending committee hearings on the GCA and other proposals for salary increases in government.
Serna emphasized that key sectors, like teachers and health workers, who stand to benefit the most from the GCA, can also get their voices heard by writing to their senators and congressmen to facilitate its passage.
The CSC regional and field offices nationwide have been collecting signatures from all government workers to support the approval of the GCA as they stand to benefit from its passage and implementation. (CSC III and PIA-Pampanga) [top]
» Mindanao LGUs share best practices
» 86 educators off for Australia study tour
» Catholic media bent for effective communication
» USEP-BEAM scholarship guidelines bared
» Barangays urged to fight terrorism
» Davao Norte drug dependents get free admission to rehab center
» e-Biz Week highlights BPO as shining industry for GenSan
» Komentaryo: Take-off ng ekonomiya
» TESDA chief leads career caravan in Tacloban
» 2,854 hopefuls take civil service exams in Region 8


text:
Werner Paul Heyd (* 21. Oktober 1920 in Stuttgart; † 8. Januar 1996 in Oberndorf am Neckar) war ein schwäbischer Journalist und Buchautor. 1945 bis 1950 studierte er in Tübingen Theologie, Philologie, Englisch, Volkskunde, Kunstgeschichte, Musikgeschichte und Musiktheorie. 1951 schloss er sein Studium als Doktor der Philologie ab. Er heiratete Grete, geborene Weisschuh, und hat eine Tochter.

Als Journalist engagierte er sich unter anderem für die deutsche Orthographie. Er war Mitglied der internationalen Kommission Rechtschreibung, die 1954 die "Stuttgarter Empfehlungen" beschlossen hat.

Von 1961 bis 1985 war er Redakteur beim Schwarzwälder Boten in Oberndorf am Neckar, seit 1965 leitender  Feuilleton-Redakteur und schrieb regelmäßig über kulturelle Veranstaltungen, Ausstellungen und Künstler. Neben der Arbeit für seine Zeitung verfasste er auch Artikel für andere Zeitschriften, Vorworte zu Büchern und eigene Bücher über Kunst und Kultur des Südwestdeutschen Raumes.

Schriften (Auswahl)
Bauernweistümer. Wetterregeln und Lostagssprüche, gesammelt von W.P. Heyd, mit Lithographien von HAP Grieshaber. Dietrich, Memmingen 1971, ISBN 3-87164-061-1
Bibliografie der zeitschriftenaufsätze zur rechtschreibreform. Im auftrag der arbeitsgemeinschaft neue rechtschreibung e.v. - agnr - zusammengestellt und eingeleitet von dr. Werner P. Heyd. Selbstverlag, Stuttgart 1958
Bibliographie der Württembergischen Geschichte. Kohlhammer, Stuttgart 1968–1974
Die Taufnamen in Nehren, Hausen, Hörschwang und Trochtelfingen. Dissertation, Universität Tübingen 1950
Der Korrektor. Werkstatt des Buches, Verlag Dokumentation, München-Pullach und Berlin, 1971, ISBN 3-7940-8824-7
Gottfried Graf und die "entartete Kunst" in Stuttgart. Mit einer Vorbemerkung von Wolfgang Kermer. Stuttgart: Staatliche Akademie der Bildenden Künste Stuttgart, 1987 (= Beiträge zur Geschichte der Staatlichen Akademie der Bildenden Künste Stuttgart, hrsg. von Wolfgang Kermer; 6)
Lachende Redaktion. Stilblüten, Druckfehler, Anekdoten. Cicero, Stuttgart 1971
Lilo Rasch-Naegele. Einführung. Belser, Stuttgart 1976
Margret Hofheinz-Döring. Eine Künstlermonographie. Stähle und Friedel, Stuttgart 1979, ISBN 3-8116-7046-8
Masken unserer Stadt: Oberndorf. Fink, Stuttgart 1973
Nicht ärgern. Ein Trost- und Schmunzelbüchlein für Druckfehlergeschädigte. Bleicher, Gerlingen und Stuttgart, 1976
Schwäbische Köpf'. Bleicher, Gerlingen 1980, ISBN 3-88350-302-9
Wetterpropheten in der Natur. Dietrich, Memmingen 1971

Weblinks

Autor
Journalist (Deutschland)
Zeitungsjournalist
Schwäbische Kultur
Deutscher
Geboren 1920
Gestorben 1996
Mann

redpajama_set_name: RedPajamaWikipedia


text:
Gloeocoryneum cinereum är en svampart som först beskrevs av Dearn., och fick sitt nu gällande namn av Weindlm. 1964. Gloeocoryneum cinereum ingår i släktet Gloeocoryneum, divisionen sporsäcksvampar och riket svampar.   Inga underarter finns listade i Catalogue of Life.

Källor

Sporsäcksvampar
cinereum


R-A-M Mounting Systems are the universal ball and socket mounting system that allow you to mount practically anything anywhere. Its family of 600 interchangeable accessories will offer you solutions to your most challenging mounting problems. Its unique design provides easy installation, mobility, strength, versatility, vibration protection and durability, all at a low cost.


Mteja is a term commonly used to refer to a customer in East Africa region.
Mteja360 is a cloud based premier customer service software solution that empowers brands and organizations to deliver consistent customer service anytime from touch down through a powerful combination of knowledge management, self-service and multi-channel engagement.
My job was to develop the brand. These were the results.
I have had the pleasure of working with Ben on the creative designs of our company. He is an ingenious designer who is constantly striving to be more creative in his designs and more efficient in every task. Ben has always been enjoyable and easy to work with. He is a proactive and collaborative problem solver and I would highly recommend him.


text:
Chubby Carrier and the Bayou Swamp Band
Chubby Carrier is undeniably "The World's Premier Zydeco Showman." Chubby Carrier and the Bayou Swamp Band are turning heads around the world and bringing Louisiana flavor to the masses. The funky zydeco band's latest release, "Zydeco Junkie," earned one of the highest musical accolades when it was named Best Zydeco or Cajun Album during the 53rd annual Grammy Awards celebration in February 2011. In addition to the coveted Grammy, the band was honored with OffBeat magazine's Best of the Beat award when it named "Zydeco Junkie" as the Best Zydeco Album. Furthermore, the 2010 Big Easy Music Awards awarded the group for Best Zydeco. www.chubbycarrier.com


text:
De vlag van Bernisse is op 15 augustus 1988 bij raadsbesluit vastgesteld als de gemeentevlag van de Zuid-Hollandse gemeente Bernisse. De vlag kan als volgt worden beschreven:

De Andreaskruizen op de vlag zijn ontleend aan het gemeentewapen, en kwamen oorspronkelijk voor in het wapen van de heerlijkheid Putten. Ze symboliseren op de vlag de plaatsen Abbenbroek, Heenvliet, Oudenhoorn en Zuidland op het eiland Voorne en de plaatsen Geervliet en Simonshaven op het eiland Putten. De golvende blauwe lijn stelt de Bernisse voor, die de gemeente doorsneed. De kleuren groen en wit kwamen voor in het wapen en de vlag van Zuidland.

Op 1 januari 2015 ging Bernisse samen met Spijkenisse op in de gemeente Nissewaard. De vlag kwam daardoor als gemeentevlag te vervallen.

Verwante afbeeldingen

Cultuur in Nissewaard
Bernisse


text:
Home » News » Claranet launches MPLS superfast broadband services across Ireland
Claranet launches MPLS superfast broadband services across Ireland
January 7, 2019 Claranet Limited
Faster and more powerful internet connectivity will enable Irish businesses to take advantage of the latest technologies.
Irish businesses are being given a connectivity boost thanks to Claranet, who will be rolling out MPLS Superfast Broadband across the country. Expanding on its current MPLS Ethernet and Broadband offering, the new service will offer lightning fast speeds of up to 100Mbps, filling the gap between the existing broadband services which Claranet currently provides.
As cloud services and web applications become more popular and increasingly sophisticated, businesses are expecting their technology provider to offer higher bandwidth and faster download speeds. Claranet are looking to the future by rolling out a powerful and reliable MPLS network infrastructure that can cope with any technical requirements. The superfast broadband will be available to all businesses across Ireland and Claranet is expecting an extremely high demand for the new service.
Many large commercial organisations, especially those in retail and finance, are looking for enhanced network connectivity that can cope with continual fluctuations in usage and is capable of processing large volumes of data during times of peak demand. Claranet's new MPLS Superfast Broadband will enable companies of all sizes to take advantage of the latest technologies and applications, including AI, chatbots, immersive AR and VR, which will improve their customer experience offering.
Smaller offices will also benefit from the new service, as additional sites can be easily incorporated into the company's wider network estate while allowing applications such as Skype or video conferencing to be fully utilised. When coupled with Claranet Online, MPLS Superfast Broadband offers IT departments complete visibility of their entire digital network estate, including service details, the status of the connectivity and bandwidth utilisation.
Dave Palmer, Head of Network Design at Claranet UK, talked about the growing demand for improved network connectivity:
Businesses across the country are capitalising on the latest innovations, including cloud computing, Internet of Things and Artificial Intelligence which all depend on having a fast, powerful and reliable internet connection to operate effectively. Our MPLS Superfast Broadband service will empower Irish businesses to take advantage of these sophisticated technologies, enabling them to achieve their digital transformation objectives and vastly improve their customer experience offering."
Claranet will offer a fully managed service and oversee the whole process, from installation to configuring the MPLS network, without having to purchase additional VPN hardware devices. It will also install a direct internet line for any business that does not have an existing connection so they can take advantage of the new service.
Claranet strengthens its Mobile Broadband service to meet growing demands for mobility
Enlarged mobile broadband data tariffs of up to 50GB to provide new flexibility to businesses who have high...
Claranet records strong growth in FY18 with 49% increase in global revenue
Organic growth and strategic acquisitions drive Claranet's turnover to £321.6m for the year ended 30 June 2...
Lack of IT security training is leaving businesses open to data breaches, says Claranet research
Both technical teams and general staff need more frequent guidance on recognising and dealing with cybersecurity threats. New research by global technology services provider Claranet has revealed...
Claranet makes a significant leap on The Sunday Times Top Track 250 for the second year running to reach 45th place
Claranet climbs 78 places in 2019 through organic growth, cementing their position among Britain's fastest-growing privately-owned businesses. Technology services provider Claranet has achieved...
Majority of UK businesses are failing to address technical debt, says Claranet research
Work needs to be done to better manage technical debt levels and reduce the barriers to change and improvement. New research by technology services provider Claranet has revealed that technical...
Claranet named in Gartner's Magic Quadrant for Data Center Outsourcing and Hybrid Infrastructure Managed Services, Europe for second year
Claranet has been positioned in Gartner's Magic Quadrant for "Data Center Outsourcing and Hybrid Infrastructure Managed Services, Europe" (DCO/HIMS), for the second successive year. In this Magic...
Retailers need to start infrastructure preparations now to strike gold this Golden Quarter, says Claranet
Claranet issues warning to retailers to start making preparations now or risk losing customers. Black Friday and Cyber Monday have become a fixture in the British retail calendar, and a...
Claranet achieves AWS Digital Customer Experience Competency status
Global technology services provider Claranet has announced that it has achieved Amazon Web Services (AWS) Digital Customer Experience Competency status. This designation recognises that Claranet...
Half of businesses lack skills needed to effectively manage cloud security, says Claranet research
Migration to hyperscale providers is commonplace, but disconnect between cloud adoption and awareness of cloud security remains. A new survey by global technology services provider Claranet has...
Claranet Builds on Google Cloud MSP Initiative
Claranet, today announced that it has deepened their standing in the Google Cloud MSP Initiative as a premier partner, giving Google Cloud customers the ability to drive more value from their...
Claranet Wins Google Cloud EMEA Breakthrough Partner of the Year Award
Claranet has received the 2018 Google Cloud EMEA Breakthrough Partner of the Year award. This award was presented at the Partner Summit at Google Cloud Next'19 in San Francisco, and comes in...
Businesses opening up to security risks by failing to gain grasp of DevSecOps
DevOps approaches have become a fixture in most businesses, but integration with security operations is lagging behind. New research commissioned by global technology services provider Claranet...
Claranet named in The Sunday Times International Track 200 for third consecutive year
Technology services provider moves up to 38th place in rankings of the UK's fastest growing privately-owned businesses in the mid-market Technology services provider Claranet has been ranked 38th...
Enlarged mobile broadband data tariffs of up to 50GB to provide new flexibility to businesses who have high data usage requirements Claranet has upgraded its Mobile Broadband offering with new...
Organic growth and strategic acquisitions drive Claranet's turnover to £321.6m for the year ended 30 June 2018, with a first quarter annualised run rate for FY19 of £350m. Claranet, the global...
Todd Salmon joins NotSoSecure to drive US growth
Industry expert joins leading penetration testing and ethical hacking company to fuel continued expansion. Leading ethical hacking and penetration testing company NotSoSecure, part of the Claranet...
Human error is to blame for poor cloud security, not the infrastructure itself, warns Claranet
Global technology services provider points to automation and fully-accredited partners as way to avoid cloud security vulnerabilities. A lack of knowledge and an overreliance on manual change...
Claranet acquires Dutch IT services provider Quinfox
Acquisition enhances Claranet's capabilities in the healthcare and accountancy sectors Claranet has acquired Dutch IT services provider Quinfox, a specialist in providing digital services for...
Nation state-backed cyberattacks may take headlines, but the risk from everyday hackers remains most prominent
Actions of national agencies may lead to fear amongst businesses, but leaders must remain wise to the more common threats. Last week, the UK government accused Russia's GRU intelligence service of...
Claranet makes a significant leap on The Sunday Times Top Track 250
Claranet climbs 55 places in recognition of a successful year, cementing company's position amongst fastest growing privately-owned businesses Claranet has achieved the rank of 123rd in The Sunday...
Claranet consolidates its security expertise with official launch of Global Cyber Security unit
New unit eases access for customers to unique capabilities of Sec-1 and NotSoSecure Claranet has announced the official launch of its Cyber Security unit, designed to give customers access to...
A poor understanding of data is hampering efforts to drive a positive customer experience, says Claranet
Research indicates that 51 per cent of UK businesses struggle to draw valuable insights from data that they collect In today's digital world, data is a vital asset that gives organisations the...


text:
How long will a 220Ah battery last?
Passive Solar Building Construction: Everything You Need to Know
Is a 13kW Solar System Right for Your Home?
The Different Grades of Solar Panels
How Solar Batteries Work During a Power Outage
How Much Solar Power Do You Need to Run a Freezer?
Residential Solar Power in 2023
3 Drawbacks to Storing Solar Energy in Batteries
How to connect solar panels to your electrical system
The BrightSource Energy Company owns the Ivanpah solar plant.
Yes, a home can be 100% solar powered!
The Cost of a 3kW Off-Grid Solar System
The Average Cost Of A 3Kw Off-Grid Solar System.
A 3kW off-grid solar system typically costs between $5,000 and $10,000. The cost of the system will vary depending on the size of the system, the type of solar panels used, the location of the system, and the installer.
If you're looking to go completely off-grid with your solar power system, you'll need to factor in the cost of batteries and a backup generator. The average 3kW off-grid solar system will cost around $6,000.
The average cost of a 3kW off-grid solar system is $7,500. This includes the cost of the solar panels, inverter, batteries, and installation. Off-grid solar systems are a great way to save money on your electric bill, and they're also good for the environment.
The Average Payback Period For A 3Kw Off-Grid Solar System.
cdn.fixr.com
The average payback period for a 3kW off-grid solar system is approximately 8 to 10 years. This means that the average homeowner will see a return on their investment within this timeframe. Solar power is a great way to save money on your energy bill, and it is also an environmentally-friendly option. If you are considering going solar, be sure to do your research and get quotes from multiple companies.
The Average Return On Investment For A 3Kw Off-Grid Solar System.
r0.meetsite.com
In recent years, the average return on investment (ROI) for a 3kW off-grid solar system has been between 20 and 30 percent.
With the cost of a 3kW system falling between $7,500 and $10,000, the average ROI is around $2,500.
However, the ROI for an off-grid solar system can vary greatly depending on the cost of the system, the location of the system, the availability of sunlight, and the amount of electricity used.
The average return on investment (ROI) for a 3kW off-grid solar system is approximately 12%. This means that for every $1,000 you invest in a 3kW off-grid solar system, you can expect to see a return of $120 over the course of 10 years.
Off-grid solar systems are a great way to invest in your future, and with an ROI of 12%, they are a smart financial investment as well. If you are looking to invest in an off-grid solar system, 3kW is a great size to start with.
The average return on investment for a 3kW off-grid solar system is about 20%. This means that for every $1,000 that you invest in a 3kW off-grid solar system, you can expect to receive about $200 back in savings over the course of the system's lifetime. While the initial investment may be higher than for a grid-tied system, the savings from not having to pay for electricity can quickly add up, making an off-grid solar system a wise investment for many people.
The Pros And Cons Of Investing In A 3Kw Off-Grid Solar System.
When it comes to going off the grid, solar power is one of the most popular options. But is it worth the investment? Here are the pros and cons of investing in a 3kW off-grid solar system.
3kW off-grid solar systems are a great investment for those looking to become more energy independent. These systems can provide enough power to cover the average home's energy needs, and can even be used to generate income through the sale of surplus power to the grid. However, there are a few things to consider before investing in an off-grid solar system.
The first is the initial investment. While the cost of solar panels has come down significantly in recent years, a 3kW system will still set you back a few thousand dollars. There are government incentives available in some countries to offset the cost of installation, but these vary from place to place.
The second is maintenance. Solar panels require very little maintenance, but the batteries that store the power generated by the panels will need to be replaced every few years. This can add to the initial investment, but is still much cheaper than paying for grid-based electricity.
The third is site selection. Not all homes are suitable for off-grid solar systems. If your home is in an area with lots of trees, for example, the panels will need to be positioned carefully to maximize sunlight exposure. In some cases, it may not be possible to get enough sunlight to power the system, and a backup generator will be required.
Overall, investing in a 3kW off-grid solar system is a great way to save money and become more energy independent. With proper planning and maintenance, these systems can provide years of trouble-free operation.
When making the decision to go solar, there are many factors to consider. One important factor is whether or not you want to go off-grid. An off-grid solar system is a great option for those who want to be independent and not rely on the grid. However, there are also some drawbacks to going off-grid.
The biggest advantage of an off-grid solar system is that you are not reliant on the grid. This means that if the grid goes down, you will still have power. This is a great option for those who live in areas where the grid is unreliable or for those who want to be prepared for a power outage.
The biggest disadvantage of an off-grid solar system is the initial cost. An off-grid solar system is more expensive than a grid-tied system. However, the long-term savings of not having a monthly electric bill can outweigh the initial cost. Another disadvantage of an off-grid system is that you are responsible for maintaining the system. This means that you will need to regularly clean and maintain your solar panels to ensure they are working properly.
Overall, the pros and cons of an off-grid solar system should be considered when making the decision to go solar. For those who want to be independent and not rely on the grid, an off-grid system is a great option. However, the initial cost and maintenance of an off-grid system should be considered before making the switch.
The Best Way To Finance A 3Kw Off-Grid Solar System.
The best way to finance a 3kW off-grid solar system is through a solar lease or power purchase agreement (PPA). With a solar lease or PPA, you can finance your system with little to no money down and pay a fixed monthly payment for the electricity that your system produces. This payment is usually lower than your current electricity bill, so you can save money each month on your energy costs.
The Benefits Of Owning A 3Kw Off-Grid Solar System.
txsolarsystems.com
3kW off-grid solar systems are becoming increasingly popular, as they offer a number of benefits over traditional grid-tied systems. Perhaps the most appealing benefit of an off-grid system is the independence it offers. With an off-grid system, you are not reliant on the local utility company for power – meaning that you can keep your lights on even if the grid goes down.
Another benefit of an off-grid system is that it can be used to power remote locations that are not connected to the grid. This can be especially useful for cabins, RVs, or boats. And, because off-grid systems are not tied to the grid, they are often less expensive to install.
If you are considering an off-grid solar system, there are a few things to keep in mind. First, because you will be generating your own power, you will need to have batteries to store the power for times when the sun is not shining. Second, you will need to be mindful of your power usage, as you will not have an unlimited supply of power. But, if you are willing to make a few adjustments, an off-grid solar system can offer a number of benefits.
The Key Things To Consider Before Investing In A 3Kw Off-Grid Solar System.
www.tanfon.com
If you're considering investing in a 3kW off-grid solar system, there are a few key things you need to take into account. First, you need to make sure that your home is suitable for off-grid living. This means having a water source, a way to dispose of waste, and enough storage for food and supplies.
You also need to factor in the cost of the system itself, as well as the cost of batteries and other components. Solar systems can be a significant investment, so it's important to do your research and make sure you're getting the best value for your money.
Finally, you need to be prepared for the reality of living off-grid. This means being comfortable with doing without some of the conveniences of modern life, like reliable electricity and running water. It can be a challenge, but it's also an exciting and rewarding way to live.
There are a few key things to consider before investing in an off-grid 3kW solar system. The first thing to consider is the cost of the system. The initial investment for an off-grid solar system can be quite high, but the long-term savings can be significant. Another thing to consider is the amount of sunlight that the system will receive. An off-grid solar system will only work if there is enough sunlight to power it. If the system is not receiving enough sunlight, it will not work properly. Finally, you need to consider the maintenance of the system. Off-grid solar systems require very little maintenance, but it is important to make sure that the system is regularly checked to ensure that it is working properly.
If you're considering investing in a 3kW off-grid solar system, there are a few key things you should take into account before making your decision. First, consider the cost of the system and whether it's within your budget. Second, think about the maintenance and upkeep required to keep the system running properly. Third, evaluate the potential return on investment you could see from the system. Finally, make sure you understand the risks involved in any off-grid solar investment. By taking these factors into consideration, you can make a more informed decision about whether a 3kW off-grid solar system is right for you.
How many 12V batteries does it take to power a house?
Can You Buy Just One Solar Panel? And Install It Yourself?
How to Choose the Right Size Battery for Your 12V Fridge
Reducing the Cost of Solar Panels
The Pros and Cons of Solar Panels vs. Batteries


text:
Appalachian Fall
Dispatches from Coal Country on What's Ailing America
By Jeff Young and The Ohio Valley Resource
Unabridged Audio Download
LIST PRICE: AU$ 16.99
A searing, on-the-ground examination of the collapsing coal industry—and the communities left behind—in the midst of economic and environmental crisis.
Despite fueling a century of American progress, the people at the heart of coal country are being left behind, suffering from unemployment, the opioid epidemic, and environmental crises often at greater rates than anywhere else in the country. But what if Appalachia's troubles are just a taste of what the future holds for all of us?
Appalachian Fall tells the captivating true story of coal communities on the leading edge of change. A group of local reporters known as the Ohio Valley ReSource shares the real-world impact these changes have had on what was once the heart and soul of America. Including stories like:
-The miners' strike in Harlan County after their company suddenly went bankrupt, bouncing their paychecks
-The farmers tilling former mining ground for new cash crops like hemp
-The activists working to fight mountaintop removal and bring clean energy jobs to the region
-And the mothers mourning the loss of their children to overdose and despair
In the wake of the controversial bestseller Hillbilly Elegy, Appalachian Fall addresses what our country owes to a region that provided fuel for a century and what it risks if it stands by watching as the region, and its people, collapse.
Photograph by J. Tyler Franklin, Louisville Public Media
Jeff Young is the managing editor of Ohio Valley ReSource, a regional journalism collaborative reporting on economic and social change in Kentucky, Ohio, and West Virginia. The ReSource includes seven public media outlets across the three states, and aims to strengthen news coverage of the area's most important issues. Jeff previously worked for West Virginia Public Broadcasting and was a Washington correspondent for the Public Radio International program "Living on Earth." Jeff grew up near Huntington, West Virginia, and studied journalism and biology at Marshall University and the University of Charleston. His reporting has been recognized with numerous awards, and he was named a 2012 Nieman Journalism Fellow at Harvard University. He lives in Louisville with his wife, Helen, and their daughters, Hazel and Louisa.
The Ohio Valley Resource
Publisher: Tiller Press (August 11, 2020)
"A collection of on-the-ground reporting from one of the country's most misunderstood and misrepresented regions.
Before the 2016 election, Donald Trump promised Appalachians that the coal-mining industry would come roaring back; since then, it remains on life support thanks to competing energy sources hammering a business that, for its workers, is economically and literally toxic. In Hillbilly Elegy (2016), J.D. Vance blamed the region's woes on lack of initiative among its residents, but a host of unique pressures trap the area in poverty. Such clarity comes thanks to the reporting of Ohio Valley ReSource, a media collective launched in 2016 by seven public media outlets in Kentucky, Ohio, and West Virginia. This book, drawn from the collective's reporting and overseen by Young, its managing editor, shows how mining companies have dodged taxes and fines while polluting the region and eluding blame for the illnesses their practices have caused; how exploitative pharmaceutical companies bred the opioid epidemic; and how efforts to launch retraining and revitalization programs tend to disappoint: "How do you bring in people and businesses if you can't promise them a clean glass of water?" one story points concludes.But while the articles paint stark portraits of the region's troubles, the reporting team doesn't indulge in ruin-porn clichés about the region; rather, they deliver profiles of people shouldering ahead despite governmental and corporate missteps—e.g., farmers making an uneasy transition into hemp farming and activist efforts to better hold mining companies accountable. The reporting doesn't aspire to flashy style or epic sweep—the articles are modeled after Sunday-newspaper features—the plainspoken reporting grabs the attention.Bemoaning the newfound emphasis on fracking, one man laments: "I don't understand why fossil fuel extraction is the only kind of job this area is offered. We want jobs that won't kill us."
Blunt, essential reading on today's Appalachia that is less elegiac and more forward-thinking than most." —Kirkus Reviews
Book Cover Image (jpg): Appalachian Fall
Author Photo (jpg): Jeff Young


Enjoy your planning and revel even more with All 0 Promocode.club's great Acronis promotion codes!
Choose a Acronis coupon you would like to use from Promocode.club. Press use Acronis code box, which is located just below. Now your web browser should copy the All 0 Acronis code for you, although it is best to make sure and copy it manually. The http://www.acronis.com web page will open in a new window for you. Go to their Acronis checkout section and find the Promotional Keycode box. Paste your Acronis coupon code there and click apply.


What is a moderate Muslim? Someone who drinks alcohol, lives a normal lifestyle, does not believe in Jihad and at the same time carries a Muslim name because he comes from a Muslim family? Is this a moderate muslim or is this not a muslim at all?


At the home of Sheila Fawcett.
Maintaining the churchyard is a major, on-going task. If you can help at any of the working parties you will be vrey welcome! If you can bring your own gardening gloves and hand tools, that's ideal, but there will be some spare tools available to use. You don't have to stay for the full time shown - all efforts are appreciated!


Stateless - Your component layer ends up becoming stateless, and only responsible for accepting props and rendering them.
Functional - With your props being composed in functions, they become easier to expand as your requirements grow.
Providers - With Proppy's providers, you can set application-wide global object accessible anywhere in your components tree.
Interoperable - Integrating other libraries to your components layer becomes a breeze with the suite of functions that Proppy provides you.
Testing - With clear separation between props generation and components, you can now unit test them separately with ease.
Freedom - Since Proppy connects to your favourite UI rendering library, you have the freedom to switch with minimal effort.


Aetna considers sipuleucel-T (Provenge) medically necessary for the treatment of adults with metastatic castrate-resistant prostate cancer who are asymptomatic or minimally symptomatic with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, and who have no liver metastases and a life expectancy of greater than 6 months (see Appendix).
Treatment of urogenital malignancies (e.g., bladder cancer).
Aetna considers use of sipuleucel-T in combination with abiraterone acetate (Zytiga), enzalutamide (Xtandi), or ipilimumab (Yervoy) experimental and investigational due to lack of evidence supporting safety and efficacy of these combinations.
Note: Footnotes for Precertification Required* Precertification of sipuleucel-T is required of all Aetna participating providers and members in applicable plan designs. For precertification of sipuleucel-T, call (866) 503-0857, or fax (866) 267-3277.
CPB 0806 - Cabazitaxel (Jevtana).
Provenge (sipuleucel‐T) is the first in a class of drugs called active cellular immunotherapies. Agents in this class are designed to stimulate a patient's own immune system. Provenge (sipuleucel‐T) works by stimulating T‐cell immunity against prostatic acid phosphatase, a protein also known as prostatic specific acid phosphatase that is produced in large amounts by prostate cancer cells. The mature, autologous antigen ‐presenting cells (APCs), contained by Provenge (sipuleucel‐T), are co‐cultured with a recombinant fusion protein containing prostatic acid phosphatase. These activated antigen‐loaded APCs can now potentially stimulate a T cell response against prostate cancer cells.
Provenge (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Provenge (sipuleucel‐T) is intended solely for autologous use and is supplied as a 250 mL suspension containing autologous CD54+ cells in Lactated Ringer's Injection and supplied in an infusion bag labeled for the specific recipient.
Prostate cancer, accounting for 33 % of all male cancers worldwide, is the second leading cause of cancer death in men, exceeded only by lung cancer. The disease is histologically evident in as many as 34 % of men during their fifth decade of life and in up to 70 % of men aged 80 years old and older. In the United States, prostate cancer represents the most common cancer among men, with an estimated 192,280 new cases diagnosed in 2009. The median survival for men with metastatic castrate-resistant prostate cancer is 1 to 2 years, with improvements in survival seen primarily with cytotoxic chemotherapy (docetaxel-based therapies). In the field of metastatic castration-resistant prostate cancer, systemic therapy options are limited and survival benefit remains to be seen with the new therapies. Staging of prostate cancer entails the size of the tumor, if lymph nodes are affected, if the tumor has metastasized, and the appropriate course of treatment. Circulating tumor cells may provide prognostic information and will likely become an important aspect of future clinical decision-making (Lassi and Dawson, 2010).
Standard systemic treatment of prostate cancer today is comprised of anti-hormonal and cytostatic agents. Vaccine therapy of prostate cancer is attractive because of the presence of tumor-associated antigens such as prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), prostate-specific membrane antigen, and others. Most prostate cancer vaccine trials have demonstrated some activation of the immune system, limited clinical success, and few adverse effects. One strategy to overcome the problem of limited clinical success of vaccine therapies in prostate cancer could be strict patient selection. The clinical course of patients with prostate cancer (even in those with PSA relapse following surgery or radiotherapy with curative intention, or those with metastatic disease) can vary significantly. In patients with organ-confined prostate cancer, the most promising immunotherapeutic approach would be an adjuvant therapy following surgery or radiotherapy. Patients with PSA relapse following surgery or radiotherapy could also benefit from immunotherapy because tumor burden is usually low. However, most patients in prostate cancer vaccine trials had metastatic hormone-refractory prostate cancer (HRPC). High tumor burden correlates with immune escape phenomena. Nevertheless, 2 years ago, it was reported, for the first time, that a tumor vaccine can prolong survival compared with placebo in patients with HRPC. This was demonstrated with the vaccine sipuleucel-T (APC-8015; Provenge), a mixture of cells obtained from the patient's peripheral blood by leukapheresis followed by density centrifugation and exposition. The biologics license application for this vaccine was denied by the U.S. Food and Drug Administration (FDA) in mid-2007, however, because the trial had failed to reach the primary endpoint (prolongation of time to tumor progression). Another interesting approach is a vaccine made from whole tumor cells: GVAX. This vaccine is presently being studied in phase III trials against, and in combination with, docetaxel. The results from these trials will become available in the near future. Besides the precise definition of the disease status of patients with prostate cancer, combinations of vaccine therapy with radiotherapy, chemotherapy, and/or hormonal therapy are approaches that look promising and deserve further investigation (Doehn et al, 2008).
Sipuleucel-T is an immunotherapeutic cellular product, which includes autologous dendritic cells pulsed ex vivo with a recombinant fusion protein (PA2024) consisting of granulocyte macrophage colony-stimulating factor and PAP. It is designed to stimulate the patient's T-cells to recognize and attack prostate cancer cells that express PAP antigen (Harzstark and Small, 2008).
In a phase III clinical trial, Small and colleagues (2006) evaluated the safety and effectiveness of sipuleucel-T in patients with metastatic, asymptomatic HRPC. A total of 127 patients were randomly assigned in a 2:1 ratio to receive 3 infusions of sipuleucel-T (n = 82) or placebo (n = 45) every 2 weeks. On disease progression, placebo patients could receive APC8015F, a product made with frozen leukapheresis cells. Of the 127 patients, 115 patients had progressive disease at the time of data analysis, and all patients were followed for survival for 36 months. The median for time to disease progression (TTP) for sipuleucel-T was 11.7 weeks compared with 10.0 weeks for placebo (p = 0.052, log-rank; hazard ratio [HR], 1.45; 95 % confidence interval [CI]: 0.99 to 2.11). Median survival was 25.9 months for sipuleucel-T and 21.4 months for placebo (p = 0.01, log-rank; HR, 1.70; 95 % CI: 1.13 to 2.56). Treatment remained a strong independent predictor of overall survival after adjusting for prognostic factors using a Cox multi-variable regression model (p = 0.002, Wald test; HR, 2.12; 95 % CI: 1.31 to 3.44). The median ratio of T-cell stimulation at 8 weeks to pre-treatment was 8-fold higher in sipuleucel-T-treated patients (16.9 versus 1.99; p < 0.001). Sipuleucel-T therapy was well-tolerated. The authors concluded that while the improvement in the primary end point of TTP did not achieve statistical significance, this study suggested that sipuleucel-T may provide a survival advantage to asymptomatic HRPC patients.
Patel and Kockler (2008) reviewed the design, efficacy, safety, dosing, therapeutic, and pharmaco-economic considerations of sipuleucel-T. English-language literature searches of Medline (1966 to September 2007) and the Cochrane Database (2007, Issue 3) were performed using the terms sipuleucel-T, APC8015, and prostate cancer vaccine. Other data sources were identified from bibliographies of selected articles and from press releases. All published articles or abstracts on human studies of sipuleucel-T for androgen-independent prostate cancer (AIPC) were reviewed for inclusion. Manufacturer Web sites, FDA documents, and the clinical trials registry were used to obtain information regarding ongoing clinical trials. Androgen-independent prostate cancer is an incurable disease with a median survival rate of 18 to 20 months. Docetaxel-based chemotherapy is currently the only FDA-approved treatment for AIPC with a survival benefit (2.4 months). Sipuleucel-T is a novel active cellular immunotherapy under investigation for the treatment of metastatic, asymptomatic AIPC. In clinical trials, the primary endpoint of TTP was not met; however, an under-powered analysis of data suggests that sipuleucel-T prolongs survival by a median of 4.5 months compared with placebo. Sipuleucel-T has been relatively well-tolerated, although a possible increased risk of cerebrovascular events may exist. In May 2007, the FDA did not approve the biologics license application for sipuleucel-T since the primary endpoint of the phase III trials was not met. The authors concluded that metastatic AIPC is an incurable disease that currently has limited treatment options. If improved survival is shown, sipuleucel-T may become the first approved active cellular immunotherapy for treating metastatic, asymptomatic AIPC.
Higano and colleagues (2009) examined the safety and effectiveness of sipuleucel-T in 2 identically designed, randomized, double-blind, placebo-controlled trials (D9901 and D9902A) conducted in men with advanced prostate cancer. A total of 225 patients were randomized in D9901 or D9902A to sipuleucel-T (n = 147) or placebo (n = 78), given as 3 intravenous infusions approximately 2 weeks apart. Patients were followed for survival until death or a pre-specified cut-off of 36 months after randomization. In the integrated analysis of D9901 and D9902A, patients randomized to sipuleucel-T demonstrated a 33 % reduction in the risk of death (HR, 1.50; 95 % CI: 1.10 to 2.05; p = 0.011; log-rank). The treatment effect remained strong after performing adjustments for imbalances in baseline prognostic factors, post-study treatment chemotherapy use, and non-prostate cancer-related deaths. Additional support for the activity of sipuleucel-T is provided by the correlation between a measure of the product's potency, CD54 up-regulation, and overall survival. The most common adverse events associated with treatment were asthenia, chills, dyspnea, headache, pyrexia, tremor, and vomiting. These events were primarily grade 1 and 2, with durations of 1 to 2 days. The authors concluded that the integrated results of D9901 and D9902A demonstrated a survival benefit for patients treated with sipuleucel-T compared with those treated with placebo. The generally modest toxicity profile, coupled with the survival benefit, suggests a favorable risk-benefit ratio for sipuleucel-T in patients with advanced prostate cancer.
Drake and Antonarakis (2010) stated that prostate cancer is the second most common cause of cancer-related death among men in the United States. Along with initial therapy using surgery, radiotherapy, or cryotherapy, hormonal therapy is the mainstay of treatment. For men with metastatic disease, docetaxel-based chemotherapy is FDA-approved, and provides a significant survival advantage. This relative paucity of treatment options drives an ongoing quest for additional treatment modalities; among these is immunotherapy. The concept that prostate cancer is a malignancy that can be targeted by the immune system may seem counter-intuitive; certainly kidney cancer and melanoma are more traditionally thought of as immune responsive cancers. However, prostate cancer arises in a relatively unique organ and may express a number of antigens against which an immune response can be generated. More importantly, several of these agents have now demonstrated a significant survival benefit in randomized controlled clinical trials.
On April 29, 2010, the FDA approved Provenge (sipuleucel-T, Dendreon Corporation, Seattle, WA) for the treatment of asymptomatic or minimally symptomatic prostate cancer that has metastasized and is resistant to standard hormone treatment. The effectiveness of Provenge was studied in a randomized, double-blind, placebo-controlled, multi-center trial in patients with asymptomatic or minimally symptomatic metastatic HRPC. Eligible patients had metastatic disease in the soft tissue and/or bone with evidence of progression either at these sites or by serial PSA measurements. Exclusion criteria included visceral (liver, lung, or brain) metastases, moderate-to-severe prostate cancer-related pain, and use of narcotics for cancer-related pain. A total of 512 patients were randomized in a 2:1 ratio to receive Provenge (n = 341) or control (n = 171). The median age was 71 years, and 90 % of the patients were Caucasian; 35 % of patients had undergone radical prostatectomy, 54 % had received local radiotherapy, and 82 % had received combined androgen blockade. All patients had baseline testosterone levels less than 50 ng/ml; 48 % of patients were receiving bisphosphonates and 18 % had received prior chemotherapy, including docetaxel. A total of 82 % of patients had an Eastern Cooperative Oncology Group performance status of 0; 58 % had primary Gleason scores of 4 or more; 44 % had bone and soft tissue disease; 48 % had bone-only disease; 7 % had soft tissue-only disease; and 43 % had greater than 10 bony metastases. Patients treated with Provenge showed an increase in overall survival of 4.1 months. The median survival for patients receiving Provenge treatments was 25.8 months, as compared to 21.7 months for those who did not receive the treatment. Overall, Provenge reduced the risk of death by 22.5 % compared to the control group (HR = 0.775).
The NCCN Prostate Panel added sipuleucel-T as a category 1 recommendation for first-line treatment of asymptomatic patients with castration-resistant prostate cancer, and a 2a recommendation for second-line treatment for minimally symptomatic patients. The NCCN guidelines (2018) state that sipuleucel-T is appropriate for patients with ECOG performance status 0-1. It is not recommended for patients with liver metastases or a life expectancy less than 6 months.
Provenge is administered intravenously in a 3-dose schedule administered at about 2-week intervals (range of 1 to 15 weeks). It is administered over a period of about 60 minutes. Almost all of the patients who received Provenge had some type of adverse reaction. Common adverse reactions included back pain, chills, fatigue, fever, headache, joint ache, and nausea. The majority of adverse reactions were mild or moderate in severity. Serious adverse reactions, reported in about 25 % of the patients receiving Provenge, included some acute infusion reactions and stroke. Cerebrovascular events, including hemorrhagic and ischemic strokes, were observed in 3.5 % of patients in the Provenge group compared with 2.6 % of patients in the control group.
Provenge (sipuleucel‐T) is intended solely for autologous use.
Acute infusion reactions have been observed in patients treated with Provenge (sipuleucel‐T). In the event of an acute infusion reaction, the infusion rate may be decreased, or the infusion stopped, depending on the severity of the reaction. To minimize potential acute infusion reactions such as chills and/or fever, it is recommended that patients be premedicated orally with acetaminophen and an antihistamine such as diphenhydramine approximately 30 minutes prior to administration. Appropriate medical therapy should be administered as needed. Closely monitor members with cardiac or pulmonary conditions.
Provenge (sipuleucel‐T) is not routinely tested for transmissible infectious diseases and may transmit diseases to health care professionals handling the product. Universal precautions should be followed.
Use of either chemotherapy or immunosuppressive agents (such as systemic corticosteroids) given concurrently with the leukapheresis procedure or Provenge (sipuleucel‐T) has not been studied. Provenge (sipuleucel‐T) is designed to stimulate the immune system, and concurrent use of immunosuppressive agents may alter the efficacy and/or safety of Provenge (sipuleucel‐T). Therefore, members should be carefully evaluated to determine whether it is medically appropriate to reduce or discontinue immunosuppressive agents prior to treatment with Provenge (sipuleucel‐T).
Phase III clinical trials investigating the efficacy and safety of Provenge (sipuleucel‐T) excluded patients who had received systemic glucocorticoids in the previous 28 days and patients who had undergone chemotherapy within the previous 3 months. The survival findings were consistent across multiple subgroups in Phase 3 studies of Provenge (sipuleucel‐T) in men with metastatic castrate resistant prostate cancer. Provenge (sipuleucel‐T) increased median survival by 4.1 months compared to the control group (p=0.032). This absolute survival improvement offers a favorable risk/benefit profile given that the safety profile was consistent with prior studies. Importantly, the placebo arm demonstrated a median survival of 21.7 months indicating that the benefit was from drug effect versus poor performance in the control arm. Additionally, after adjustment for docetaxel use following Provenge (sipuleucel‐T), the Hazard Ratio maintained its robustness (HR=0.763; p‐value=0.036). Provenge (sipuleucel‐T) extended median overall survival by 4.1 months (25.8 months for Provenge vs. 21.7 months for placebo). Provenge (sipuleucel‐T) reduced the risk of death by 22.5%, though it is important to realize the AIPC is incurable. Provenge (sipuleucel‐T) improved 3 year survival by 38% compared to placebo. Member demographics were well balanced which included Gleason score, ECOG status, >10 bone metastasis, and bisphosphonate use. Baseline labs were also well balanced with similar PSA, Alk Phos, Hg, WBC, and LDH. Analyses of time to disease progression did not meet statistical significance in any Phase 3 study of Provenge (sipuleucel‐T). Provenge (sipuleucel‐T) is not recommended for patients with a life expectancy of less than six months.
Combination immunotherapy with Provenge plus other agents has been studied in patients with prostate cancer. Rini and colleagues (2006) noted that bevacizumab is a recombinant antibody against vascular endothelial growth factor, a pro-angiogenic protein with inhibitory effects on antigen-presenting cells (APC). These researchers carried out a clinical trial to determine the PSA and immunomodulatory effects of combination immunotherapy with sipuleucel-T plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Patients with androgen-dependent prostate cancer who had received prior definitive therapy with non-metastatic, recurrent disease as manifested by a rising PSA of between 0.4 ng/ml and 6.0 ng/ml were enrolled. Sipuleucel-T was given intravenously (i.v.) on weeks 0, 2, and 4. Bevacizumab was given at a dose of 10 mg/kg i.v. on weeks 0, 2, 4, and every 2 weeks thereafter until toxicity or disease progression. Changes in PSA were recorded and the PSA doubling time (PSADT) was calculated. Immune response versus PA2024 was measured at baseline and after treatment by T-cell proliferation and interferon-gamma enzyme-linked immunospot (ELISPOT) assays. A total of 22 patients were treated. One patient achieved a greater than or equal to 50 % decrease in PSA; 9 patients exhibited some decrease in PSA from baseline, ranging from 6 % to 72 %, with the PSA of 3 patients decreasing at least 25 %. The median pre-treatment PSADT for the 20 evaluable patients was 6.9 months and the median post-treatment PSADT was 12.7 months (p = 0.01). All patients demonstrated induction of an immune response against PA2024. The authors concluded that the combination of sipuleucel-T and bevacizumab induces an immune response and modulates PSA in patients with biochemically recurrent prostate cancer.
Antonarakis and Drake (2010) stated that an emerging paradigm for the treatment of prostate cancer focuses on using immunotherapy plus check-point antagonists or in combination with conventional therapies in patients with early-stage disease. Such approaches are likely to yield optimal results, but must carefully be explored in well-designed phase II studies.
Lubaroff (2012) presented important information about the current state of the art for vaccine immunotherapy of prostate cancer. It included important preclinical research for each of the important prostate cancer vaccines to have reached clinical trials. To-date, the only prostate cancer vaccine that has completed phase III trials and has been approved and licensed by the FDA is Sipuleucel-T, which immunizes patients against the prostate-associated antigen PAP. A phase III trial is currently underway using the vaccinia-based PSA vaccine Prostvac-TRICOM. Other immunotherapeutic vaccines in trials include the Ad/PSA vaccine Ad5-PSA and the DNA/PAP vaccine. A cellular vaccine, GVAX, has been in clinical trials, but has not seen continuous study.
Amato and Stepankiw (2012) reviewed the development of the combination of modified vaccinia Ankara (MVA) to deliver the tumor-associated antigen 5T4 as a novel immunotherapeutic vaccine. The onco-fetal antigen 5T4 is highly expressed in 80 % of breast, kidney, colorectal, prostate and ovarian carcinomas, making it an ideal antigen for vaccine therapy. To-date, more than 3,000 doses of MVA-5T4 have been administered to patients with colorectal, renal and prostate cancer, with rare occurrences of grade 3 or 4 vaccination-related adverse events being observed. Studies have demonstrated that MVA-5T4 is safe and highly immunogenic, both as monotherapy and in combination with other standard of care therapies. Although an immune response has been observed, anti-tumor activity has been modest or absent in clinical trials. A phase III trial resulted in the development of an immune response surrogate that is to be applied to all future MVA-5T4 clinical trials. The authors concluded that with minimal side effects and the ability to produce a strong immunogenic response, MVA-5T4 is a viable addition to the cancer therapy arsenal.
Reardon et al (2013) stated that outcome for glioblastoma (GBM) remains poor. The overall survival benefit recently achieved with immunotherapeutics -- ipilimumab for melanoma and sipuleucel-T for prostate cancer -- support evaluation of immunotherapies for other challenging cancers, including GBM. Much historical dogma depicting the central nervous system (CNS) as immune-privileged has been replaced by data demonstrating CNS immune-competence and active interaction with the peripheral immune system. Several glioma antigens have been identified for potential immunotherapeutic exploitation. Active immunotherapy studies for GBM, supported by pre-clinical data, have focused on tumor lysate and synthetic antigen vaccination strategies. Results to-date confirmed consistent safety, including a lack of autoimmune reactivity; however, modest efficacy and variable immunogenicity have been observed. The authors concluded that these findings underscored the need to optimize vaccination variables and to address challenges posed by systemic and local immunosuppression inherent to GBM tumors. Moreover, they noted that additional immunotherapy strategies are also in development for GBM; future studies may consider combinatorial immunotherapy strategies with complimentary actions.
Goldberg (2013) stated that although molecularly targeted inhibitors are of great interest in treating sarcoma patients, immunotherapy is emerging as a plausible therapeutic modality because of the recent advances in other cancer types that may be translated to sarcoma. The licensing of ipilimumab for melanoma and sipuleucel-T for prostate cancer, and the remarkable success of immunotherapy for some childhood cancers, suggest a role for immunotherapy in the treatment of tumors like sarcoma. The author described the current advances in immunotherapy and how they can be applied to sarcoma, and discussed the recent literature and selected clinical trials. Evidence supporting treatment with immunotherapy alone in sarcoma as well as potential incorporation of immunotherapy into treatment for sarcoma was reviewed. The author concluded that sarcoma is a disease for which new treatments are needed. Immunotherapies have different mechanisms of action from most current therapies and could work in concert with them. Recent advances in sarcoma biology and cancer immunotherapy suggest that the understanding of the immune system has reached the point where it can be used to augment both targeted and multi-modality therapy for sarcoma.
Gulley et al (2014) stated that PSA-TRICOM (PROSTVAC) is a novel vector-based vaccine designed to generate a robust immune response against PSA-expressing tumor cells. These researchers presented an overview of both published studies and new data in the evaluation of immune responses to the PSA-TRICOM vaccine platform, currently in phase III testing. Of 104 patients tested for T-cell responses, 57 % (59/104) demonstrated a greater than or equal to 2-fold increase in PSA-specific T cells 4 weeks after vaccine (median 5-fold increase) compared with pre-vaccine, and 68 % (19/28) of patients tested mounted post-vaccine immune responses to tumor-associated antigens not present in the vaccine (antigen spreading). The PSA-specific immune responses observed 28 days after vaccine (i.e., likely memory cells) are quantitatively similar to the levels of circulating T cells specific for influenza seen in the same patients. Measurements of systemic immune response to PSA may under-estimate the true therapeutic immune response (as this does not account for cells that have trafficked to the tumor) and do not include antigen spreading. Furthermore, although the entire PSA gene is the vaccine, only 1 epitope of PSA is evaluated in the T-cell responses. Because this therapeutic vaccine is directed at generating a cellular/Th1 immune response (T-cell co-stimulatory molecules and use of a viral vector), it is not surprising that less than 0.6 % of patients (2/349) tested have evidence of PSA antibody induction following vaccine. The authors concluded that this suggested that post-vaccine PSA kinetics were not affected by PSA antibodies. Moreover, they stated that an ongoing phase III study will evaluate the systemic immune responses and correlation with clinical outcomes.
Jochems et al (2014) previously reported the clinical results of a phase I trial combining ipilimumab with a vaccine containing transgenes for PSA and for a triad of co-stimulatory molecules (PROSTVAC) in patients with metastatic castration-resistant prostate cancer. A total of 30 patients were treated with escalating ipilimumab and a fixed dose of vaccine. Of 24 chemotherapy-naïve patients, 58 % had a PSA decline. Combination therapy did not exacerbate the immune-related adverse events associated with ipilimumab. These researchers presented updated survival data and an evaluation of 36 immune cell subsets pre- and post-therapy. Peripheral blood mononuclear cells were collected before therapy, at 13 days and at 70 days post-initiation of therapy, and phenotyped by flow cytometry for the subsets of T cells, regulatory T cells, natural killer cells, and myeloid-derived suppressor cells. Associations between overall survival (OS) and immune cell subsets prior to treatment, and the change in a given immune cell subset 70 days post-initiation of therapy, were evaluated. The median OS was 2.63 years (1.77 to 3.45). There were trends toward associations for longer OS and certain immune cell subsets before immunotherapy: lower PD-1(+)Tim-3(NEG)CD4EM (p = 0.005, adjusted p = 0.010), higher PD-1(NEG)Tim-3(+)CD8 (p = 0.002, adjusted p = 0.004), and a higher number of CTLA-4(NEG) Tregs (p = 0.005, adjusted p = 0.010). These investigators also found that an increase in Tim-3(+) natural killer cells post- versus pre-vaccination associated with longer OS (p = 0.0074, adjusted p = 0.015). The authors concluded that these results should be considered as hypothesis generating and should be further evaluated in larger immunotherapy trials.
Lubaroff et al (2014) noted that pre-clinical studies demonstrated the ability of an adenovirus/PSA (Ad/PSA) vaccine to induce strong anti-PSA immune responses, and these responses were capable of destroying PSA-secreting mouse prostate tumors. A series of pre-clinical studies have demonstrated the superiority of the Ad/PSA vaccine to other PSA vaccines for the induction of anti-PSA immune responses, the ability of Ad/PSA vaccination combined with cytokine gene therapy and the TLR9 agonist CpG to enhance the anti-prostate tumor immunotherapy, and the reduction of negative regulatory elements when the vaccine was combined with 5-fluoruracil administration. A phase I clinical trial of the Ad/PSA vaccine in men with metastatic castrate-resistant prostate cancer demonstrated the safety of the vaccine even at the highest single dose permitted by the FDA. Currently, a phase II trial of the Ad/PSA vaccine is underway treating patients in 2 protocols. Thus far 81 patients have been enrolled and vaccinated. The authors concluded that early results demonstrated the induction of anti-PSA T cell responses, and the majority of patients evaluated at this time had demonstrated an increase in PSA doubling times.
Simpson et al (2015) stated that the National Institute for Health and Care Excellence (NICE) invited Dendreon, the company manufacturing sipuleucel-T, to submit evidence for the clinical- and cost-effectiveness of sipuleucel-T for asymptomatic or minimally symptomatic, metastatic, non-visceral hormone-relapsed prostate cancer patients in whom chemotherapy is not yet clinically indicated, as part of NICE's single technology appraisal process. The comparator was abiraterone acetate (AA) or best supportive care (BSC). The School of Health and Related Research at the University of Sheffield was commissioned to act as the Evidence Review Group (ERG). The ERG had several concerns regarding the data and assumptions incorporated within the company's cost-effectiveness analyses and conducted exploratory analyses to quantify the impact of making alternative assumptions or using alternative data inputs. The deterministic incremental cost-effectiveness ratio (ICER) for sipuleucel-T versus BSC when using the ERG's preferred data and assumptions was £108,585 per quality-adjusted life-year (QALY) in the whole licensed population and £61,204/QALY in the subgroup with low PSA at baseline. The ERG also conducted an incremental analysis comparing sipuleucel-T with both AA and BSC in the chemotherapy-naive subgroup. Sipuleucel-T had a deterministic ICER of £111,682/QALY in this subgroup, when using the ERG's preferred assumptions, and AA was extendedly dominated. The ERG also concluded that estimates of costs and benefits for AA should be interpreted with caution given the limitations of the indirect comparison. The NICE Appraisal Committee noted that the ICER for sipuleucel-T was well above the range usually considered cost-effective, and did not recommend sipuleucel-T for the treatment of asymptomatic or minimally symptomatic, metastatic, non-visceral hormone-relapsed prostate cancer.
Geczi and colleagues (2016) provided information regarding advance and main achievements in the immunotherapy of genitourinary, particularly renal cell and prostate cancer. Nivolumab treatment became the new standard of care in locally advanced or metastatic renal cell cancer after failure on tyrosine kinase inhibitor treatment. Sipuleucel-T prolonged survival in patients with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer; but had no effect on progression-free survival. The authors stated that based on the results of phase I/II trials anti-PD-1/PD-L1 monoclonal antibodies are a new hope in the treatment of urothelial bladder cancer; regarding germ cell tumors basic research is ongoing.
Cattrini and associates (2016) stated that in the past few years, cancer immunotherapy has changed the natural history and treatment strategies of a number of solid tumors, including melanoma and lung cancer. The anti-PD-1 nivolumab showed a survival benefit compared with everolimus in the 2nd-line treatment of renal cell carcinoma, resulting in a radical shift in perspective in the treatment of this neoplasia and suggesting a new scenario beyond tyrosine kinase inhibitors. Check-point inhibitors might also improve the treatment of urothelial cancer, considering the promising results achieved so far and the relatively low effectiveness of currently available treatments. Sipuleucel-T was the first approved immunotherapy for PC, showing a clear benefit in OS, and paved the way for the clinical testing of other novel cancer vaccines. The authors provided a comprehensive overview of the current knowledge and new perspectives of immunotherapy in the treatment of urogenital malignancies.
In a phase I clinical trial, Scholz and colleagues (2017) examined the effects of sipuleucel-T combined with escalating doses of ipilimumab (IPI) in progressive metastatic castrate-resistant prostate cancer (mCRPC). A total of 9 men with progressive mCRPC were treated prospectively with SIP-T followed immediately by IPI with one of the following doses of IPI: 1 mg/kg at 1 week after SIP-T; 1 mg/kg at 1 and 4 weeks after SIP-T; or 1 mg/kg at 1, 4, and 7 weeks after SIP-T; 3 patients were evaluated at each level. Cancer-specific immunoglobulins directed at granulocyte-macrophage-colony-stimulating factor (GM-CSF)/ PAP fusion protein (PA2024) and PAP were measured prior to SIP-T, after SIP-T, 1 week after IPI, every other month for 5 months, then every 3 months for an additional 12 months. Adverse events of SIP-T were consistent with previous reports; IPI only caused a transient grade 1 rash in 1 patient. Median age, Gleason score, and number of previous hormonal interventions were 77 years, 8, and 3, respectively; 8 men had bone metastases and 1 had lymph node metastasis. Statistically significant increases in serum immunoglobulin G (IgG) and IgG-IgM specific for PA2024 and PAP occurred after SIP-T. An additional statistically significant increase in the afore-mentioned immunoglobulins -- above the levels achieved by SIP-T -- occurred after IPI. Median clinical follow-up was 36 months (range of 26 to 40 months); 3 patients died from progressive disease after 9, 18, and 20 months. Out of the remaining 6 patients, 5 of them needed further treatment that included abiraterone acetate, enzalutamide, radium-223 dichloride, and spot radiation. One patient had an undetectable PSA, who did not receive any other treatment except spot radiation. Median PSA at last follow-up for the surviving patients was 3.8 (range of 0.6 to 7.47). The authors concluded that in this small trial, the addition of IPI to SIP-T was well-tolerated; IPI increased immunoglobulins specific for the PA2024 protein and PAP above the level achieved with SIP-T alone. They stated that firm conclusions regarding the effectiveness of SIPIPI in such a small series such as this one are difficult to derive; moreover, these data support ongoing trials of SIPIPI in mCRPC with larger patient numbers, albeit with higher doses of IPI.
Member has expected survival of at least 6 months.
Footnotes for LHRH agonists* LHRH agonists (analogs) include leuprolide (Lupron, Viadur, Eligard), goserelin (Zoladex), triptorelin (Trelstar), and histrelin (Vantas). Degarelix (Firmagon) is an LHRH antagonist that is thought to work like LHRH agonists. See CPB 0501 - Gonadotropin-Releasing Hormone Analogs and Antagonists.
According to the FDA-approved labeling of Provenge, the recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals. In controlled clinical trials, the median dosing interval between infusions was 2 weeks (range of 1 to 15 weeks); the maximum dosing interval has not been established. Administration of more than 3 complete doses of sipuleucel-T is considered experimental and investigational.
Source: Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649-655.
Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Vaccines for metastatic hormone-refractory prostate cancer. Emerging Drug List No. 66. Ottawa, ON: CCOHTA; December 2005.
Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461-3467.
Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24(19):3089-3094.
Rini BI, Weinberg V, Fong L, et al. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (Provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer. 2006;107(1):67-74.
McKarney L. Sipuleucel-T (Provenge®): Active cellular immunotherapy for advanced prostate cancer. Issues in Emerging Health Technologies, Issue 101. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health (CADTH); September 2007.
Doehn C, Böhmer T, Kausch I, et al. Prostate cancer vaccines: Current status and future potential. BioDrugs. 2008;22(2):71-84.
Harzstark AL, Small EJ. Sipuleucel-T for the treatment of prostate cancer. Drugs Today (Barc). 2008;44(4):271-278.
Patel PH, Kockler DR. Sipuleucel-T: A vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann Pharmacother. 2008;42(1):91-98.
Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009;115(16):3670-3679.
Drake CG, Antonarakis ES. Update: Immunological strategies for prostate cancer. Curr Urol Rep. 2010;11(3):202-207.
U.S. Food and Drug Administration (FDA). FDA approves a cellular immunotherapy for men with advanced prostate cancer. FDA News. Rockville, MD: FDA; April 29, 2010. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm210174.htm. Accessed April 30, 2010.
Antonarakis ES, Drake CG. Current status of immunological therapies for prostate cancer. Curr Opin Urol. 2010;20(3):241-246.
Adams E. Bibliography: Treatments for metastatic castrate-resistant prostate cancer. Boston, MA: VA Technology Assessment Program (VATAP); July 2010.
Lassi K, Dawson NA. Update on castrate-resistant prostate cancer: 2010. Curr Opin Oncol. 2010;22(3):263-267.
Dendreon Corporation. Provenge (sipuleucel-T) suspension for intravenous infusion. Prescribing Information. Seattle, WA: Dendreon Corporation; 2010. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM210031.pdf. Accessed April 30, 2010.
National Comprehensive Cancer Network (NCCN). Prostate cancer. NCCN Clinical Practice Guidelines in Oncology v.2.2010. Fort Washington, PA: NCCN; 2010.
BlueCross BlueShield Association (BCBSA), Technology Evaluation Center (TEC). Special report: Vaccines for the treatment of prostate cancer. TEC Assessment Program. Chicago, IL: BCBSA; April 2010;24(6).
Kantoff PW, Higano CS, Shore ND, et al; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-422.
National Horizon Scanning Centre (NHSC). Sipuleucel-T (Provenge) for metastatic castration resistant prostate cancer - first line. Horizon Scanning Review. Birmingham, UK: National Horizon Scanning Centre (NHSC); April 1, 2011.
Hall SJ, Klotz L, Pantuck AJ, et al. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. J Urol. 2011;186(3):877-881.
Mark D, Samson DJ, Bonnell CJ, et al. Outcomes of sipuleucel-T therapy. Technology Assessment Report. Prepared by the BlueCross BlueShield Association Technology Evaluation Center Evidence-based Practice Center for the Agency for Healthcare Research and Quality (AHRQ) under contract no. HHSA 290 2007 10058 I. Project No. CANP0610. Rockville: Agency for Healthcare Research and Quality (AHRQ); February 10, 2011.
National Comprehensive Cancer Network (NCCN). Prostate cancer. NCCN Clinical Practice Guidelines in Oncology v.4.2013. Fort Washington, PA: NCCN; 2013.
Scher HI, Halabi S, Tannock I, et al. Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148-1159.
Lubaroff DM. Prostate cancer vaccines in clinical trials. Expert Rev Vaccines. 2012;11(7):857-868.
Amato RJ, Stepankiw M. Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer. Future Oncol. 2012;8(3):231-237.
Reardon DA, Wucherpfennig KW, Freeman G, et al. An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines. 2013;12(6):597-615.
Goldberg JM. Immunotherapy of sarcomas. Curr Opin Oncol. 2013;25(4):390-397.
Schlom J, Hodge JW, Palena C, et al. Therapeutic cancer vaccines. Adv Cancer Res. 2014;121:67-124.
Uhlman MA, Bing MT, Lubaroff DM. Prostate cancer vaccines in combination with additional treatment modalities. Immunol Res. 2014;59(1-3):236-242.
Gulley JL, Madan RA, Tsang KY, et al. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer. Cancer Immunol Res. 2014;2(2):133-141.
Jochems C, Tucker JA, Tsang KY, et al. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: Immune correlates. Cancer Immunol Immunother. 2014;63(4):407-418.
Lubaroff DM, Vaena D, Brown JA, et al. Vaccine immunotherapy for prostate cancer: From mice to men. Immunol Res. 2014;59(1-3):229-235.
Simpson EL, Davis S, Thokala P, et al. Sipuleucel-T for the treatment of metastatic hormone-relapsed prostate cancer: A NICE single technology appraisal; an evidence review group perspective. Pharmacoeconomics. 2015;33(11):1187-1194.
Geczi L, Ladanyi A, Vajdics T, et al. Immunotherapy in the treatment of genitourinary cancers. Magy Onkol. 2016;60(1):41-45.
Cattrini C, Dellepiane C, Cavo A, et al. Immunotherapy for genitourinary cancer: State of the art and new perspectives. Anticancer Drugs. 2016;27(7):585-599.
Yi R, Chen B, Duan P, et al. Sipuleucel-T and androgen receptor-directed therapy for castration-resistant prostate cancer: A meta-analysis. J Immunol Res. 2016;2016:4543861.
Scholz M, Yep S, Chancey M, et al. Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer. Immunotargets Ther. 2017;6:11-16.
National Comprehensive Cancer Network (NCCN). Sipuleucel-T. NCCN Drug & Biologics Compendium. Fort Washington, PA: NCCN; 2018.


Olympic medalist Gretchen Bleiler headlines the Hall of Fame's Class of 2019.
Topping the list of new Hall of Fame members is Aspen's Gretchen Bleiler, an Olympic silver medalist in halfpipe at the 2006 Turin Olympics and Colorado's most successful snowboard athlete. She will be joined by Jeff Gorsuch, an Aspen ski retailer and philanthropist with a focus on kids and skiing; the late Martin Hart, who helped transform Steamboat Springs into one of the foremost ski resorts in the nation; and Steve Raymond, co-founder of the Adaptive Spirit program and a major fundraiser for the U.S. Paralympic Ski Team.
These four new inductees will be joined by the 2019 Pioneer Hall of Fame selection, Jake Hoeschler of Winter Park, who revolutionized the ski retail industry with his exclusive ski liability insurance program, which now includes millions of dollars of coverage.
Tickets for the gala are currently on sale, with reserved individual tickets priced at $325, while tables of 10 are available, starting at $3,750. A $250 general individual ticket option is also available but does not include seating location preference. The 2019 Gala will be hosted at the Vail Marriott Mountain Resort in Lionshead.
To purchase tickets or for additional information, please visit the museum website at http://www.snowsportsmuseum.org or call (970) 476-1876. All proceeds from the Hall of Fame Gala will benefit the Colorado Snowsports Museum.
The five Hall of Fame inductees were elected from a field of 14 nominees that also included Johnny Buxman (Vail), Tracey and Tim Canaday (Denver), Eugene Dayton (Breckenridge), Rik Heid (Vail), Bob Kunkel (Durango), Ted Martin (Vail), Ellen Post Foster (Vail), Scott Rawles (Breckenridge) and Annie Varielle-Savath (Telluride).
Hall of Fame candidates are nominated under the established criteria of Athlete, Sport Builder, Inspirational or Pioneer categories, with the Hall of Fame Nomination Committee evaluating and confirming the nominees to move onto the final ballot. The 140-member Hall of Fame Voting Panel is comprised of current Hall of Fame members, key ski industry representatives and Hall's board of directors and Nomination Committee.
Colorado's most successful snowboard athlete, Gretchen Bleiler, has made her mark as an athlete, an entrepreneur and an advocate for causes important to her. In a professional career that spanned nearly 20 years, Bleiler was the top star in her sport of halfpipe from 2002 through 2010. At the age of 18, she was invited to compete in the Winter X Games. Four years later she was on top of the world, winning her first of four X Games gold medals, world superpipe championships gold and her second Vans Triple Crown title. She dominated qualifying for the 2006 Olympics, going on to win Olympic silver.
Following her Olympic medal, she used the platform to build a business base as an athlete-entrepreneur, designing a signature clothing line for Oakley and providing creative input to K2 Snowboards. Since retiring as an athlete in 2014, Bleiler has turned her attention to blending her entrepreneurial and advocacy interests. Through her entire career as one of the world's greatest snowboarders, Gretchen Bleiler has represented the face of Colorado and her home of Aspen.
Jeff has been a Sport Builder his entire life. A third-generation member of Colorado's iconic Gorsuch family, Jeff was exposed to the ski racing and retail sides of the ski industry since he could crawl. Jeff moved to Aspen after college and has run the family's Aspen retail operation for the past 25 years. Growing up Gorsuch, Jeff inherited a deep appreciation for the trailblazers of the ski industry and has devoted his spare time to giving back.
From an Aspen community perspective, his philanthropic focus is on kids, working with local organizations like the Aspen Valley Ski and Snowboard Club, the Aspen Education Foundation and the Aspen Community School. He has been lauded for his kids ski program that provides up to 300 pair of skis, boots and poles annually to people who can't afford them. He also has served as the president of the Aspen Valley ski & Snowboard Club and on the boards of the Aspen Education Foundation and Aspen Community School.
Martin Hart envisioned and implemented a vision for community collaboration, international air access and financial success for the Steamboat Springs community and resort. In 1970, LTV Recreational Development purchased Steamboat Springs Ski Area with the plan to modernize and make it a year-round resort. Ultimately though, it was Martin Hart who laid the foundation for what Steamboat is today.
Within three seasons, $15 million was spent to make Steamboat a first-rate ski area. By the end of 1986, more than $30 million in improvements had been made and Steamboat was considered one of the top four ski areas in Colorado. The expansion of the Hayden airport was a game-changer, allowing greater access to Steamboat. Throughout his involvement with Steamboat, Martin worked hard to have Steamboat hold onto its old west charm. Martin T. Hart believed in the importance of building a ski area that was good business for everyone — investors, townspeople, skiers, and Colorado as a whole. Martin passed away in 2014.
Jake Hoeschler revolutionized the ski retail industry with his exclusive ski liability insurance program, which now includes millions of dollars of coverages. While racing on the World Cup and Pro Race Circuits throughout the '60s and '70s Jake noticed how ski shops were struggling to stay in business because of their liability exposure to the threat of frivolous lawsuits. In 1988 Hoeschler founded the National Ski Insurance Program to make skiing a safer sport while also protecting the retailer from an onslaught of unsubstantiated insurance claims.
Hoeschler used his insurance and law background to bring together the Risk Managers from top binding companies to implement the indemnification program that exists today. The Program now has its own attorneys, adjusters, claims handlers and expert witnesses. The shop personnel are trained and certified through a series of videos, webinars, risk management manuals and certification testing. Many shops owners say they would not be in business today if it weren't for this program. Most every shop in the U.S. is part of this program.
Steve Raymond co-founded the Colorado Adaptive Spirit organization in 1995 and has served for 25 years as its volunteer chairman. He was also part of the group of Denver cable television leaders who created SkiTAM in 1995. The annual three-day fundraising event brings together world-class adaptive racers with telecommunications corporate sponsors and their guests. To date, more than 20,000 business executives and guests have participated in this event. Financially, Adaptive Spirit accounts for 45% of the USOC Adaptive Ski Team operating budget.
With Adaptive Spirit financial support, the USOC Paralympic team has excelled in international competition. Under his leadership, Adaptive Spirit has raised $20 million which has had a significant impact on the success of the United States Olympic Committee's Paralympic program. Steve's efforts have played an important role in the success of Colorado adaptive athletes. Their success, in turn, gives Colorado a world-class reputation as the North American epicenter for adaptive skiers to live, train, compete, and win.